StockpollyBeta
Get App
Popularity #3,816
NERV · NASDAQ · Biotechnology

Minerva Neurosciences (NERV)

Develops roluperidone for negative symptoms of schizophrenia through a confirmatory Phase 3 trial.

$3.61
vs last close−0.20 (−5.25%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
67764543351711
Research & development35442211125,2557
323223322311,4173
General & administrative323223322311,4173
Other expenses0000000000−16,6550
Operating income−6−7−7−6−4−5−4−3−3−5−17−11
−2−2−2−2270000−279−10928
Interest income000000000111
Interest expense222200000000
Other non-operating income0000−270000279109−28
Income before tax−8−9−9−823−4−4−3−3−284−12517
Net income from continuing operations−8−9−9−823−4−4−3−3−284−12517
Net income−8−9−9−823−4−4−3−3−284−12517
EPS, basic−$1.03−$1.19−$1.13−$1.09$2.97−$0.56−$0.50−$0.43−$0.36−$25.51−$2.86$0.36
EPS, diluted−$1.03−$1.19−$1.13−$1.09$2.97−$0.56−$0.50−$0.43−$0.36−$25.51−$2.86−$0.14
Weighted average shares, basic888888888114447
Weighted average shares, diluted888888888114479
EBITDA−6−7−6−623−4−4−3−3−284−12517
Depreciation & amortization000000000000
EBIT−6−7−6−623−4−4−3−3−284−12517